Source: Allogene Therapeutics Allogene to Initiate the ALPHA Study for ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma ALLO-647, Allogene’s Proprietary anti-CD52 Antibody, Will be Administered as Part of the Lymphodepletion Regimen Paris (France) and South San Francisco, Calif. – January 28, 2019 – Servier, an independent international pharmaceutical company and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical- stage biotechnology company pioneering the …
Fibrosis-targeting drugs may benefit patients with late-stage, metastatic breast cancer
Source: massgeneral.org From: news-medical.net A Massachusetts General Hospital (MGH) research team has found that the overgrowth of connective called fibrosis may block the effectiveness of immunotherapies against metastatic breast cancer. Their report published in PNAS also finds that plerixafor, a drug approved to mobilize blood system stem cells in the treatment of lymphoma and multiple myeloma patients, can reduce fibrosis …
Cancer: How Do You Choose the Right Doctor for You
View PostNew breast imagine modality may reduce unnecessary biopsies by up to 45 percent
By: Lisa Chamoff From: dotmed.com Researchers at Washington University in St. Louis predict a new breast imaging modality that combines ultrasound and near-infrared imaging, or diffuse light tomography, can reduce unnecessary biopsies by up to 45 percent. The team — Quing Zhu, professor of biomedical engineering at the Washington University in St. Louis School of Engineering & Applied Science and …
Innovative Ice-Free Scalp Cooling During Chemotherapy Prevents, Reduces Hair Loss for Breast Cancer Patients
Source: Henry Ford Health System From: newswise.com Breast cancer patient Laura Carey returned to work one week after beginning chemotherapy, but without a demoralizing side-effect indicative of this type of cancer treatment – hair loss. Carey is among the first breast cancer patients at the Henry Ford Cancer Institute to successfully prevent and reduce hair loss during chemotherapy by using …
OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer
Source: OncoQuest, Inc. From: prnewswire.com OncoQuest Inc., a privately held, cancer immunotherapy company, has retained the services of IQVIA, a company formed through the merger of IMS Health and Quintiles, to manage OncoQuest’s planned Phase 3 clinical study in frontline ovarian cancer with the company’s lead product candidate, oregovomab, an anti-CA-125 antibody. OncoQuest will collaborate with IQVIA, a leading global …
Cutting-edge MRI-guided radiation therapy provides real-time view of tumors
By: Ronda Wendler From: mdanderson.org An innovative new technology is now providing radiation oncologists at MD Anderson Cancer Center a real-time view of tumors while they use cancer-killing radiation beams. These live images help keep the radiation beam directly on target throughout every treatment, allowing for a degree of precision and monitoring capabilities that were not previously possible. Marriage of …
Inovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor
From: prnewswire.com Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved a sustained complete response (full remission) after subsequent treatment with a PD-1 checkpoint inhibitor. This marks the second patient with metastatic cancer observed in full remission (complete response) after treatment …
In surprising reversal, scientists find a cellular process that stops cancer before it starts
Source: Salk Institute for Biological Studies From: prnewswire.com Salk research shows that cellular recycling process, thought to fuel cancer’s growth, can actually prevent it Just as plastic tips protect the ends of shoelaces and keep them from fraying when we tie them, molecular tips called telomeres protect the ends of chromosomes and keep them from fusing when cells continually divide …
Royal United Hospital in Bath leads UK in new worldwide breast cancer trial
From: bathecho.co.uk The RUH in Bath has become the first site in the UK and Europe to recruit a patient to a worldwide study, testing a new combination of drugs to treat breast cancer. Dr Rebecca Bowen, RUH Consultant Medical Oncologist, who is leading the research study at the hospital, said: “We are delighted to be participating in such an …